All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs.

Of special interest to multiple buysiders is the launch of SMA gene therapy Zolgensma onasemnogene abeparvovec-xioi from the AveXis Inc. unit of Novartis AG, which could be the first litmus test of gene therapy's commercial potential. ...